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α–Intercalated cells (A-ICs) within the collecting duct of the kidney are critical for acid-base homeostasis. 
Here, we have shown that A-ICs also serve as both sentinels and effectors in the defense against urinary infec-
tions. In a murine urinary tract infection model, A-ICs bound uropathogenic E. coli and responded by acidify-
ing the urine and secreting the bacteriostatic protein lipocalin 2 (LCN2; also known as NGAL). A-IC–depen-
dent LCN2 secretion required TLR4, as mice expressing an LPS-insensitive form of TLR4 expressed reduced 
levels of LCN2. The presence of LCN2 in urine was both necessary and sufficient to control the urinary tract 
infection through iron sequestration, even in the harsh condition of urine acidification. In mice lacking A-ICs, 
both urinary LCN2 and urinary acidification were reduced, and consequently bacterial clearance was limited. 
Together these results indicate that A-ICs, which are known to regulate acid-base metabolism, are also critical 
for urinary defense against pathogenic bacteria. They respond to both cystitis and pyelonephritis by delivering 
bacteriostatic chemical agents to the lower urinary system.
Introduction
Urinary tract infections (UTIs) are among the most prevalent and 
resource-taxing diseases in the United States. Each year, 13.3% 
of women, 2.3% of men (1), and 3.4% of children (2) are infected, 
most commonly with Gram– uropathogenic E. coli (UPEC) (3). 
2 billion dollars per year are spent caring for infected patients (4). 
It is well known that the kidney constitutively synthesizes a num-
ber of antimicrobial peptides with broad specificity, for example 
RNAse7 (5) and the cathelicidins (6), but less is known about the 
kidney’s acute responses to UTIs. We found that the bacteriostatic 
protein lipocalin 2 (LCN2; also known as NGAL, 24p3, and SCN) 
was secreted in response to Gram– UTIs in both human cohorts 
and in a variety of mouse models. LCN2 was expressed by special-
ized cells located in distal segments of the nephron.
Lcn2 expression was first observed in embryonic and adult col-
lecting duct (CD) cells (7, 8), but its message was expressed at low 
levels. However, Lcn2 message was intensively upregulated (10- to 
1,000-fold increase; refs. 8, 9), and its protein appeared in the urine 
and in the serum (5- to 500-fold increase) within hours of stimuli 
that typically cause acute kidney injury (AKI). Inductive stimuli 
included sepsis (10–14), ischemia-reperfusion injury (IR) (9, 15–27), 
obstructive uropathy (28), nephrotoxins (15, 29–33), trauma-
rhabdomyolysis (34), kidney graft injury (35, 36), or a mixture of 
these maladies (37, 38). Sepsis was a particularly strong stimulus 
for LCN2 expression. To model our findings, we created a biolu-
minescent-fluorescent LCN2-Luc2-mCherry reporter mouse to con-
tinuously monitor LCN2 expression in real time in vivo (15). IR of 
the kidney induced bioluminescent LCN2 reporter expression in 
the kidney medulla in proportion to the intensity of the stimulus 
and identical in timing with the appearance and disappearance of 
urinary LCN2 protein (uLCN2) over 2 days. In situ hybridization 
revealed that LCN2 was expressed after IR (15) by the thick ascend-
ing limbs (TALH) and by A-ICs, but not by B-ICs or principal cells 
of the CDs. Similar data were obtained using different models of 
sepsis. In all of these cases, A-ICs consistently and prominently 
expressed LCN2, whereas the contribution of the TALH was vari-
able. These findings raised questions with respect to the role of the 
A-IC in different acute injuries. They also questioned the function 
of LCN2 in the urinary system.
LCN2 is a member of a broad group of proteins known as the 
lipocalins. Structurally, all lipocalins have a calyx created by an 
8-stranded antiparallel β-sheet that is closed back on itself to form 
a β-barrel (39), which binds a variety of ligands. During the clon-
ing of recombinant LCN2, the protein bound a bacterial molecule 
composed of 3 catechol rings held together by a triserine lactone. 
The bacterial molecule is known as enterochelin (Ent) (40), a sid-
erophore synthesized by Gram– bacteria. Ent can remove Fe from 
transferrin with high affinity (Kd, 10–49 M), but in the presence of 
LCN2, Ent:Fe3+ binds to LCN2 (Kd, 10–10 M), rerouting Ent:Fe3+ 
for degradation and preventing Fe transfer to bacteria (40, 41). In 
fact, the LCN2:Ent:Fe3+ complex is stable at pH 4.0, which implies 
that LCN2 can sequester Ent:Fe3+ in most biological fluids, even 
acidified urine (8). Fe can only be released from the LCN2:Ent:Fe3+ 
complex in acidified lysosomes, following the reduction of Fe 
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and the proteolytic cleavage of LCN2 (42). Hence, LCN2 arrests 
extracellular bacterial growth by chelating Ent:Fe3+, limiting its 
bioavailability in solution (40, 43, 44). Conversely, Lcn2–/– mice 
succumb to systemic (peritoneal) infection with Ent-expressing 
laboratory strains, due to unchecked growth (43, 45), which sug-
gests that chelation of the siderophore is critical for innate defense. 
Because we have previously observed high levels of LCN2 in the 
circulation and urine of both human (11, 45) and mouse models 
of sepsis (including cecal ligation and puncture, which produced a 
531-fold increase in kidney Lcn2 mRNA; N. Paragas and J. Barasch, 
unpublished observations), we speculated that kidney LCN2 sup-
presses the growth of Ent-producing bacteria, not only in circula-
tion, but also in the urinary system.
The dominant mechanism of bacterial clearance in the urogeni-
tal tract includes urinary flow and regular bladder emptying, as well 
as shedding of infected cells (46). In addition, the urogenital sys-
tem constitutively expresses antimicrobial proteins (AMPs) that are 
released into the urine, most strikingly by loop of Henle and CDs 
(HBD1, refs. 47, 48; THP, refs. 49–52; and lactoferrin, ref. 53), as well 
as by ICs (RNase7, ref. 5). Some of these molecules can be directly 
upregulated by urinary infections (e.g., cathelicidin by 3- to 8-fold, 
ref. 48) or indirectly by cytokines that are stimulated by the urinary 
infection (e.g., HBD1, ref. 48), while other AMPs are constitutively 
expressed (54, 55). The AMPs typically disrupt the phospholipid 
membranes of different types of microorganisms, including both 
bacteria and fungi, rather than target a specific species (56, 57). 
RNase7, for example, inhibits Gram– E. coli, Pseudomonas, and Proteus 
as well as Gram+ Enterococcus and Staphyloccocus (58). Lactoferrin and 
THP also inhibit both Gram+ and Gram– organisms (59). LCN2 dif-
fers from these defense mechanisms not only because of the specific-
ity of its target (Ent siderophores produced by Gram– organisms), 
but also because it is rapidly upregulated orders of magnitude by 
both bacterial and aseptic causes of AKI.
Here we provide evidence that the A-IC plays a role in immune 
defense by secreting LCN2 and H+ in order to suppress urinary 
tract pathogens and ascending pyelonephritic infections during 
the course of tissue damage. To test these ideas, we examined 
human urine samples and created different models of UTI using a 
variety of genetically modified mice.
Results
LCN2 expression in human and murine UTI. To identify the expres-
sion pattern of uLCN2 in humans with UTI, we analyzed data col-
lected from patients admitted to the hospital from the Emergency 
Department (60). In this cohort, we found a number of patients 
with acute UTIs. In infected patients (urinary leukocyte esterase– 
and urine culture–positive [LE+Cx+]; n = 43) who were selected 
because they did not have additional renal diseases, we found that 
supernatant uLCN2 was upregulated on average 10-fold compared 
with uninfected patients (LE–Cx–; n = 514) (P < 0.001; Figure 1A) 
(60). Where quantitative bacteriologic data were available in the 
hospital record, we found that uLCN2 correlated with urinary 
CFUs (uCFUs; n = 141; Figure 1B) in LE+ patients (>30 wbc per 
high-powered field). In addition, when clinic patients presented 
with dysuria, frequency, urgency, and urinary findings including 
hematuria and LE+ urine (>30 wbc per high-powered field) and 
were treated with antibiotics, uLCN2 expression was suppressed 
within 3 days (n = 4; P < 0.01; Figure 1C). These data demonstrat-
ed that supernatant uLCN2 was associated in a dose-dependent, 
reversible fashion with uCFUs, although the wide variation in 
uLCN2 suggested that a multistep process was required to induce 
Lcn2 expression.
To model the UTI, we challenged C57BL/6 mice with small vol-
umes of the UPEC strain CFT073 (20 μl of 5 × 108 CFU/ml; refs. 
61–63) by transurethral catheterization (TU) (62, 64). We then 
serially assayed the urinary supernatant to monitor both uLCN2 
Figure 1
LCN2 is markedly upregulated in human and mouse UTI. (A) uLCN2 expression in LE+Cx+ (100 ng/ml; IQR 30–300 ng/ml; n = 43) versus 
LE–Cx– patients (14.2 ng/ml; IQR 7.4–35.3 ng/ml; n = 514) in an Emergency Department cohort lacking other forms of kidney disease. 
(B) Relationship between uLCN2 and uCFU in all LE+ Emergency Department patients (LE+ and <104 uCFU [limit of detection], 45 ng/ml 
uLCN2, IQR 20–150 ng/ml, n = 75; LE+ and 104–105 uCFU, 250 ng/ml, IQR 40–425 ng/ml, n = 21; LE+ and >105 uCFU, 520.2 ng/ml, IQR 236.7–
1,126 ng/ml, n = 45). (C) Suppression of uLCN2 by antibiotics (Pre, 600 ng/ml, IQR 533–700 ng/ml; Post, 83.0 ng/ml, IQR 21–129 ng/ml) in 
patients presenting to clinic with dysuria, frequency, urgency and LE+ (>30 wbc per high-powered field), hematuria, and mucus threads (n = 4). 
Values represent median and IQR.
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and uCFUs longitudinally over the course of 7 days. Similar to our 
patient data, supernatant uLCN2 grossly mirrored uCFUs at both 
peak (days 1–3) and resolution (days 4–5) phases of infection (n = 7; 
Figure 2, A and B). uLCN2 expression levels reached 10 μM, but then 
declined rapidly. Hence, UPECs acutely and reversibly induced the 
expression of a graded amount of uLCN2 in mice and in humans.
LCN2 is necessary and sufficient to suppress UPECs. LCN2 acts as a 
narrow-spectrum antimicrobial by chelating the Ent siderophore 
(8). To determine its importance in our model of UTI, we deleted 
murine Lcn2 by BAC recombineering (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI71630DS1). Lcn2loxP/loxP mice were generated and mated with 
EIIa-Cre mice (65) to generate Lcn2–/–, a global knockout in a 
C57BL/6 background (see Methods and Supplemental Figure 1). 
These mice developed normally and were fertile. However, Lcn2–/– 
mice (n = 6) took a significantly longer time than littermates to 
resolve a small inoculum of UPEC (20 μl of 5 × 108 CFU/ml); ele-
vated uCFUs were identified in Lcn2–/– mice on days 1–5 after TU 
(P < 0.05, Figure 2A). In contrast, WT Lcn2+/+ littermates (n = 7) 
cleared the infection over 4 days, in parallel with their expression of 
uLCN2 (Figure 2, A and B).
LCN2 suppresses bacterial growth by binding Ent (40). To test 
whether the LCN2-Ent interaction was essential for the suppression 
of urinary bacterial growth in vivo, we challenged Lcn2-deleted mice 
and WT controls with a CFT073 UPEC mutant lacking entF (66). 
Unlike infection with WT CFT073 UPEC (Figure 2A), we did not find 
a significant difference in urine, bladder, or kidney cultures 1 day 
after TU with Ent-null CFT073 UPEC (Figure 2C), which indicated 
that LCN2 activity depends on the expression of bacterial Ent.
uCFUs have been found to parallel bladder and kidney CFUs 
in different mouse models of UTI (67). To examine whether this 
correlation also applied to Lcn2–/– and Lcn2+/+ littermates, we mea-
Figure 2
LCN2 is necessary and sufficient to suppress UTI. (A) Longitudinally sampled WT C57BL/6 mouse urine (n = 7 per time point) demonstrated 
faster clearance of Ent+ uCFUs than that of sibling-matched Lcn2–/– mice (n = 6 per time point). *P < 0.05, Mann-Whitney test. (B) Longitudinal 
measurements of uLCN2 by immunoblot, in the same urine samples as in A, correlated with uCFUs. Lanes for 0–3 days and for 4–7 days were 
run on different gels, but with the same in-gel LCN2 standards. (C) In contrast, there was no significant difference in uCFUs in Lcn2–/– versus WT 
mice inoculated with Ent-null UPEC. (D) Bladder CFUs in Lcn2–/– mice (n = 9) exceeded those in WT mice (n = 5) and mirrored the difference in 
uCFUs at 1 day after infection with Ent+ UPEC. (E) LCN2 (5 μM; n = 3) suppressed the growth of UPEC in urine (pH 5.8). P < 0.0001.
Figure 3
Response of UPEC to LCN2 and DFO. UPEC 
were grown in M9 medium with (A) LCN2 
(5 μM; n = 5) or (B) DFO (50 μM; n = 5) for 
30 minutes. Note the upregulation of Ent syn-
thetic enzymes (entA and entF) and recep-
tors (fepA and iroN), aerobactin synthetic 
enzymes (iucA and iucD) and receptors 
(iutA), and heme receptors (chuS), which 
indicates that LCN2 induced Fe starvation 
and widespread activation of compensatory 
pathways, similar to Fe restriction by DFO.
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sured CFUs in bladder homogenates obtained 24 hours after TU. 
Similar to our findings in urine samples, colonization of the blad-
der was generally higher in Lcn2–/– versus Lcn2+/+ littermates (Fig-
ure 2D). Hence, serial measurements of uCFUs, as well as bladder 
CFUs, suggested that LCN2 was required to suppress the growth 
of UPEC in acute UTIs.
Next, we tested whether LCN2 was sufficient to inhibit uri-
nary bacterial growth in vitro. We used UPEC grown to log phase 
in a Fe-restricted minimal media (M9), and then subsequently 
transferred the bacteria into urine or into a new batch of M9. 
Growth in urine (pH <6.0) was similar to growth in acidified 
M9 (pH <6.0). Addition of LCN2 (5 μM, a 5-fold molar excess 
compared with urine Fe, and an amount consistent with uLCN2 
in UTI; Figure 2B) inhibited bacterial growth in urine (n = 3; 
P < 0.0001; Figure 2E). Conversely, the addition of excess Fe 
(1 mM) to M9 cultures restored UPEC growth (data not shown), 
which indicated that LCN2 restricts Fe availability.
To further examine whether LCN2 induces bacterial Fe starva-
tion, we measured a series of Fe acquisition systems known to be 
regulated by Fe load via fur (63, 68), including the catecholates 
Ent (ent genes) and salmochelin (iro genes), the hydroxamate 
aerobactin (iuc genes) (69, 70), and their respective receptors, fepA, 
iroN (71–73), and iutA as well as the heme-scavenging chu recep-
tors (73). We found that the addition of LCN2 (5 μM; n = 5) for 
30 minutes to UPEC in M9 media upregulated genes in the fur 
regulon, including synthetic enzymes (e.g., entA and entF, 396.2- 
and 36,294.5-fold, respectively; ref. 74) and receptors (e.g., fepA 
and iroN, 18.0- and 2.94-fold, respectively; ref. 75); genes in the 
aerobactin pathway, including synthetic enzymes (e.g., iucA and 
iucD, 12,568.5- and 19.0-fold, respectively) and receptors (e.g., iutA, 
13.4-fold); and genes in the heme pathway (e.g., chuS, 26.9-fold) 
(Figure 3A), which suggested that LCN2 induces the widespread 
activation of compensatory pathways due to Fe starvation. In 
order to confirm the physiologic relevance of the growth condi-
tions, we added trace amounts of Fe to M9 to match the urinary 
concentration (806 nM; see Methods and Table 1) and found that 
LCN2 still activated Ent and aerobactin genes. To test whether 
the upregulation of bacterial siderophores by LCN2 was typical 
of Fe chelation, we tested the medicinal Fe chelator desferoxamine 
(DFO). Fe chelation with 50 μM DFO produced gene expression 
changes similar to those produced by LCN2 (n = 5; Figure 3B), 
which confirmed the notion that LCN2 induces Fe starvation. 
Hence, while UPEC express many types of siderophores (68), these 
data demonstrated that LCN2 was both necessary and sufficient 
to acutely limit UPEC growth in an Fe-dependent fashion, despite 
selectively recognizing Ent (43, 76).
The kidney medulla expresses LCN2. To localize sites of expression of 
LCN2 in acute UTI in C57BL/6 mice, we used our bioluminescent 
Lcn2-Luc2 (C57BL/6 background) reporter mice (15). The report-
ers were constructed by the placement of Luc2 at the start codon 
of the Lcn2 gene so that expression of Luc2 faithfully and quanti-
tatively paralleled the expression of Lcn2 message in the kidney in 
different types of kidney damage (15). When reporter mice were 
exposed to a UTI, we found that LCN2 bioluminescence originat-
ed from the kidney medulla (peak, 4.88 ± 0.95–fold at day 1; n = 11; 
P < 0.0001; Figure 4, A and B), which was most clearly evident 
when we explanted the urinary system and hemisected the kidney 
(Figure 4C). We confirmed the induction of LCN2 in the kidney 
by performing quantitative PCR and measuring copy number, 
which showed log-order increases in Lcn2 message (n = 5; Figure 
4D). Hence, similar to aseptic kidney injuries (15, 60), the C57BL/6 
model of UTI induced LCN2 in the medulla of the kidney.
C57BL/6 mice are known to be resistant to kidney colonization 
by bacteria (64). Moreover, our inoculum volume (20 μl) was not 
likely to generate gross vesicular-urinary reflux in the C57BL/6 
background (77). Trials with bioluminescent CFT073 UPEC 
(CFT073 UPEC-lux; 20 μl of 5 × 108 CFU/ml; n = 4; Supplemental 
Figure 2 and Figure 4, E and F) and measurement of CFUs (n = 4; 
Supplemental Figure 3) also failed to reveal obvious infection of 
the kidney (limit of detection, 102 CFU), which indicated that 
LCN2 message and medullary bioluminescence may have been 
triggered by a small number of bacteria reaching the kidney. 
Alternatively, bacterial components may have reached the kidney 
and induced LCN2. These included LPS (lipid A), which we previ-
ously found to powerfully induce high levels of LCN2 in the kid-
ney medulla (15), and Ent, which we found to induce uLCN2 and 
kidney Lcn2 message (2.8 ± 0.68–fold; n = 5; P = 0.037 at 6 hours; 
Supplemental Figure 4), consistent with cytokine activation by 
Ent in other models (78). The UPEC inoculum in C57BL/6 mice 
also induced kidney cytokines (e.g., Il1a, Il18, and Cxcl1; n = 10; 
Figure 4G), some of which are known to amplify LCN2 expres-
sion (79–81). These data indicated that urinary bacteria might 
induce uLCN2 with a variety of ligands.
In addition to the kidney medulla, uLCN2 might have also origi-
nated from bladder cells. However, while GFP-labeled UPECs (Sup-
plemental Figure 5) bound to the thin layer of bladder uroepithelia 
(Figure 5A) and induced both Lcn2 and cytokines (n = 5; Figure 5, 
B and C), the vast majority of Lcn2 transcripts were still expressed 
by kidney, rather than by bladder (P < 0.05, kidney vs. bladder tran-
scripts; Figure 4D). Additionally, bladders explanted from LPS-treat-
ed C57BL/6 mice (1 mg/kg i.p.; n = 3) secreted only 10 ng/ml LCN2 
per 12 hours (Supplemental Figure 6), representing about 0.004% 
of the uLCN2 induced by the same dose of LPS in matched mice 
(∼250 μg/ml). LCN2 may have also originated from neutrophils, 
but uLCN2 was expressed in urine supernatants even after neu-
trophil ablation with RB6-8C5 (150 μg), compared with treatment 
with control rat IgG2b (150 μg) (15, 82). In summary, whereas blad-
der epithelia and neutrophils undoubtedly contributed to soluble 
uLCN2, it appears that the kidney medulla is also an important 




Bacterial preparation of mouse LCN2
LCN2 concentration 1.80 μM
Fe concentration 1.34 μM
Fe in media
M9 minimal media 0.124 μM
Human urine 0.68 μM
Mouse urine 0.806 μM
LCN2:Fe molar ratio
Bacterial preparation of LCN2 (5 μM) 1,343
LCN2 (5 μM) in M9 minimal media (undiluted) 39.3
LCN2 (5 μM) in human urine (undiluted) 7.31
LCN2 (5 μM) in mouse urine (undiluted) 6.18
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The A-IC expresses LCN2. Since there was little evidence of coloni-
zation of the C57BL/6 kidney with UPECs in our model of UTI, we 
turned to another model of urinary infection: pyelonephritis in the 
C3H/HeN mouse. These mice are susceptible to UPEC-mediated 
pyelonephritis because they are naturally prone to vesiculoureteral 
reflux due to the Vurm1 locus (83, 84). We confirmed the reflux 
using bioluminescent CFT073 UPEC-lux, which rapidly ascended 
to the kidney (Figure 4, E and F). To locate the bacteria in the kid-
ney, we inoculated GFP-transfected UPEC (20 μl of 5 × 108 CFU/ml) 
under control of the E. coli Lac promoter (Supplemental Figure 5). 
GFP-labeled UPECs associated with a subset of CD cells, which 
expressed luminal v-ATPase (Figure 6, A and B), characteristic of 
Figure 4
Temporal and spatial expression of LCN2 in the kidney. (A–D and G) Cystitis model. (A and B) Lcn2-Luc2 (C57BL/6 background) reporter mice 
were inoculated with UPEC, and luciferase was quantified (n = 11). (C) Excised urogenital tracts (1 day after inoculation) verified that LCN2 
luminescence (arrowheads) originated from the kidney medulla. (D) Lcn2 copy number in C57BL/6 kidney and bladder before and 1 day after 
inoculation. (E and F) C57BL/6 and C3H/HeN mice inoculated with bioluminescent CFT073 UPEC-lux (20 μl of 5 × 108 CFU/ml; n = 4 each) were 
imaged on the dorsal and ventral sides for 3 days. UPEC-lux were detected 1–3 days after inoculation in C3H kidney (cystitis and pyelonephritis), 
but not in C57BL/6 kidney (cystitis). (G) Cytokine activation in C57BL/6 kidney (cystitis model; n = 10). *P < 0.05; #P < 0.001. Scale bar: 1 cm. Kd, 
kidney; g, gonad; Blad, bladder.
Figure 5
Temporal and spatial expression of LCN2 in bladder. (A) GFP-labeled UPEC in C3H bladder wall. (B) Lcn2 expression by uroepithelium (1 day 
after inoculation). (C) Cytokine activation in C3H/HeN Lpsn bladder (pyelonephritis model; n = 6). Note the consistent expression of Il1a and Il1b 
in bladder and kidney (see Figure 4G). Scale bars: 100 μm.
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A-ICs (15). In addition, in situ hybridization showed that Lcn2 
message was induced in scattered epithelia after inoculation (Fig-
ure 6C), typical of ICs. To further examine the interaction between 
UPEC and CD epithelia, we used an IC line (85, 86) and applied 
heat-killed UPECs (5 × 106 CFU; P < 0.005; Figure 6D). The bac-
teria induced LCN2 expression in an NF-κB–sensitive fashion in 
the ICs (85, 86). In addition, when we explanted epithelia directly 
from the medulla of Lcn2-Luc2–expressing kidneys (15, 43, 45) and 
treated the cells with living UPEC (P < 0.01; Figure 6E), we visu-
alized the activated LCN2-Luc2 reporter. LCN2-Luc2 activation 
reflected the bacterial burden, because treatment with antibiotics 
reversed the activation. These data implied that CD cells (ICs) can 
directly sense and respond to bacteria or their components in a 
cell-autonomous fashion.
The IC is required for bacteriostasis. To test the role of the ICs in UTI 
in vivo, we developed a method for deleting these cells from CDs. 
We sought transcription factors active in IC development by con-
verting the metanephric mesenchyme into epithelia with growth 
factors (LIF plus FGF), and then we identified transcription fac-
tors expressed with repetitive microarray analyses during tubu-
logenesis (87). The transcription factor Tcfcp2l1 was expressed in 
late stages of both mesenchymal tubulogenesis in vitro and kidney 
development in vivo (E18–P5). Deletion of this transcription fac-
tor (Tcfcp2l1fl/fl;Ksp-Cre mice; M. Werth, unpublished observations) 
abolished the IC lineage in toto, as demonstrated by v-ATPase 
staining (Figure 7, A and B). All other segments of the nephron 
developed normally, as indicated by the normal serum creatinine 
and urinary protein profiles (Supplemental Figure 7) as well as the 
normal distribution and density of segment-specific marker pro-
teins for CDs (Krt8 and calbindin; Figure 7B and data not shown), 
principal cells (Aqp2), and TALH (Tamm-Horsfall; M. Werth, 
unpublished observations). To determine whether knockout of 
ICs affects bacteriostasis, we examined the responses to UPEC and 
LPS using the same doses and protocols as in Figures 2 and 4–6. 
While WT mice responded by expressing uLCN2 (n = 6, Figure 
7C) and by acidifying the urine (n = 15, P < 0.05, Figure 7D; n = 6, 
P < 0.05, Figure 7E), IC-knockout Tcfcp2l1fl/fl;Ksp-Cre littermates 
suppressed both responses. Consistently, Tcfcp2l1fl/fl;Ksp-Cre mice 
demonstrated higher CFU levels in both bladder and urine (n = 8, 
P < 0.05, Figure 7F), which indicated that they were less fit to 
defend the urinary tract than their littermates.
ICs classically regulate acid-base balance by secreting H+. To 
evaluate whether acidification also reduced bacterial growth, we 
treated UPEC in M9 minimal media or human urine with increas-
ing H+ concentrations and found that bacterial growth was repro-
ducibly suppressed in a dose-dependent fashion in both media 
(n = 4 each; Figure 8, A and B). Because acidification inhibited the 
growth of UPEC and did not disrupt the chelation of Ent:Fe by 
LCN2 (8), these data suggested that A-ICs respond to infection 
by coordinately expressing 2 compatible bacteriostatic agents. 
Indeed, deletion of Tcfcp2l1 resulted in reduced urinary acidifica-
tion in mice stimulated by LPS or by UPEC (Figure 7, D and E).
Figure 6
UPEC bound to A-ICs. (A) In the 
C3H/HeN model of pyelonephritis, 
GFP-labeled UPEC (green) specifi-
cally bound A-ICs (marked by api-
cal v-ATPase; red; n = 4). Original 
magnification, ×40. (B) High-resolu-
tion image of UPEC-GFP bound to 
A-ICs. Original magnification, ×100. 
(C) UPEC induced Lcn2 (arrow-
heads) in C3H medullary cells/ICs 
in kidney (paraffin in situ hybridiza-
tion). (D) Treatment of an IC line 
with killed UPEC (24 hours; n = 4) 
induced Lcn2 message. NF-κB 
inhibitor (5 μM) reversed the LCN2 
signal. (E) Coculture of Lcn2-Luc2 
kidney medullary cells with living 
UPECs (3 hours) induced LCN2-
Luc2 reporters. Gentamicin reversed 
the LCN2 signal (n = 3). Note the 
luminescent wells (blue, baseline; 
green/red, activated). Scale bars: 
50 μm (A and C); 10 μm (B).
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Activation of LCN2 by TLR4. Human data demonstrated that 
uLCN2 was particularly elevated in patients with Gram– rather 
than Gram+ UTI (P < 0.05, Figure 1C and Figure 9A), suggesting 
a role for the LPS receptor TLR4 (88). To examine the physi-
ological role of TLR4 in the regulation of LCN2 expression, 
we used TLR4-defective C3H mice. Lpsd (C3H/HeJ) mice carry 
a mutation in TLR4 that renders them insensitive to LPS (88). 
The Lpsd mouse could not effectively suppress the growth of 
UPEC, as shown by higher uCFUs (n = 15, P < 0.01, Figure 9B), 
nor could they express as much LCN2 (n = 15, P < 0.05, Figure 
9C) as WT Lpsn mice (C3H/HeN or HeOuJ, n = 9). To determine 
whether TLR4 regulates additional genes, we measured the same 
cytokines that UPEC induced in the C57BL/6 kidney (e.g., Il1a 
and Il1b, Figure 5C). C57BL/6 and C3H Lpsn kidneys expressed a 
similar profile of cytokine responses to UTI, but the Lpsd mouse 
severely blunted their expression (n = 15 and 9, respectively, 
P < 0.05, Figure 9D) (79–81). To determine whether the Lpsd 
phenotype could be ascribed to TLR4 expression in the kidney 
parenchyma, we transplanted Lpsn kidneys into nephrectomized 
Lpsd hosts and vice versa, and treated the recipients with LPS 
(1 mg/kg i.p.). LPS is a powerful inducer of LCN2 in many dif-
ferent tissues (15), including Lpsn kidneys, which demonstrated 
a 15.6 ± 2.3–fold increase in Lcn2 message 
when transplanted into Lpsd hosts (n = 3); 
conversely, the Lpsd kidney (which is not a 
null mutation) generated only a 4.5 ± 2.6–
fold increase when transplanted into Lpsn 
hosts (P < 0.05, Figure 9E). In fact, adminis-
tration of LPS (1 mg/kg) specifically activat-
ed LCN2 in ICs (Figure 9F), consistent with 
their local expression of TLR4 (Figure 9G and 
ref. 89). Hence, despite many potential sys-
temic effects of LPS, these data demonstrated 
that the expression of kidney TLR4 critically 
regulates both LCN2 and IL expression in 
response to UPEC and LPS. The IC appears 
to be a critical target of TLR4 signaling.
Discussion
A-ICs regulate acid-base homeostasis by secreting H+ into the urine. 
The process involves the reiterative insertion of H+ATPase contain-
ing vesicles into the apical membrane, particularly in response to 
metabolic and respiratory acidoses (90, 91). The H+ titrates urinary 
NH3+ and HPO42–, producing acidified urine in the range of pH 4.5–
pH 6.5. It has been known for nearly a century that acidified urine 
inhibits the growth of E. coli (92) and other urinary organisms; how-
ever, A-ICs, which mediate acid-base balance, have not previously 
been assigned a dedicated role in antimicrobial defense. Here, we 
demonstrated that A-ICs sense Gram– UTIs ranging in severity from 
cystitis to pyelonephritis and respond with innate immune defenses.
A-ICs were strategically located in the CDs, where they bound 
UPEC ascending from the bladder in the pyelonephritic C3H 
mouse (Figure 4E, Figure 5, and ref. 89). A-ICs may use their 
microvilli and microplicae to contact bacterial FimH, PapG, or 
Dr (93), each of which has been shown to ligate different epi-
thelial receptors (94). Moreover, A-ICs used TLR4 (Figure 9G) to 
sense UPEC and to trigger a program that included expression of 
cytokines (Figure 9D), expression of LCN2 (Figure 6E and Figure 
9, C and F), and acidification of the urine (Figure 7, D and E). 
Even isolated and cultured kidney medullary epithelia and ICs 
Figure 7
A-ICs regulate uLCN2 and urinary pH. (A) ICs in sibling-matched Tcfcp2l1fl/fl and (B) IC-knockout Tcfcp2l1fl/fl;Ksp-Cre mice were visualized by 
immunostaining with Troma1-Krt8 (red), v-H+ATP6v1b1 (blue), and Tcfcp2l1 (green). (C and D) Deletion of IC Tcfcp2l1 suppressed (C) uLCN2 
(n = 6) and (D) acidification in response to LPS (n = 15) compared with Tcfcp2l1fl/fl littermates. (E) UPEC also induced urinary acidification in 
C57BL/6 mice (n = 6). (F) IC-knockout Tcfcp2l1fl/fl;Ksp-Cre mice were significantly less able to clear bladder and urinary bacteria 1 day after TU 
inoculation than Tcfcp2l1fl/fl mice (n = 8). *P < 0.05. Scale bars: 10 μm.
Figure 8
Acidification inhibits bacterial growth. UPEC growth was significantly suppressed by acidi-
fication in both (A) M9 media (n = 4; P < 0.0001) and (B) acidified urine (n = 4; P < 0.0001, 
pH 5.0 vs. pH 5.5, pH 5.5 vs. pH 6.0, and pH 6.0 vs. pH 6.5).
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responded to UPEC by expressing LCN2 in an NF-κB–depen-
dent fashion (Figure 6D). Constitutively expressed antimicrobi-
als, including the nonselective RNase7 (5, 58); cathelicidins, such 
as LL-37 (6, 95); and defensins (96), such as HBD1 (48), HBD2, 
and HD5 (54, 58) — as well as the inflammatory cytokine IL-18 
(97) — may also derive from A-ICs. These data demonstrated that 
A-ICs bind, sense, and respond to Gram– pathogenic bacteria in a 
cell-autonomous fashion.
To determine the physiological importance of the IC in the defense 
of the urinary tract, we used a number of approaches, including data 
from our in vitro tubulogenesis assays (98), which demonstrated a 
role for the transcription factor Tcfcp2l1 in epithelial morphogenesis 
(87). We created conditional mice (M. Werth, unpublished observa-
tions) and deleted Tcfcp2l1 in TALH and CDs, but not in other parts of 
the kidney, adrenal, spinal cord, liver, pancreas, intestine, or bladder, 
using the Ksp-Cre driver (99). In Tcfcp2l1 knockout kidneys, principal 
cells (shown by Troma staining in Figure 7, A and B), proximal tubule 
cells (shown by surrounding tubules [background green] in Figure 7), 
CDs and connecting segment (calbindin), TALH (Tamm-Horsfall), 
and glomeruli (podocalyxin) stainings were unaffected (M. Werth, 
unpublished observations), and excess proteinuria was not apparent 
(Supplemental Figure 7). Only ICs were deleted from the kidney, and 
only subtle renal tubular acidosis was evident in knockout mice fed 
normal diets (M. Werth, unpublished observations), in agreement 
with a prior report (100). Consequently, the reduced clearance from 
urine and from bladder homogenates in Tcfcp2l1 knockouts (the kid-
neys were uninfected in this predominant C57BL/6 background) was 
most likely attributable to the wholesale deletion of ICs and their 
constitutive (i.e., RNAse7, cathelicidins, defensins, and acidification) 
and regulated (i.e., LCN2) antimicrobial defenses.
Figure 9
TLR4 is required to induce LCN2 in UTI. (A) Gram– 
infections, but not Gram+ infections, induced high 
levels of uLCN2 in the subset of the Emergency 
Department patients with documented specia-
tion data, CFU counts, and no other renal disease 
(Gram+, 200.0 ng/ml, IQR 30.0–425.0 ng/ml, n = 9; 
Gram–, 400.0 ng/ml, IQR 135.0–775.0 ng/ml, n = 77). 
Both Gram+ and Gram– patients had >100,000 
CFU/ml urine. (B) uCFUs were significantly lower, 
and (C) kidney Lcn2 and (D) kidney Il1 levels were 
significantly higher, in C3H Lpsn (n = 9) versus 
Lpsd (n = 15) mice after inoculation (pyelonephritis 
model). (E) Lpsn kidneys transplanted into Lpsd 
hosts demonstrated a 3-fold greater response to 
LPS (as assessed by kidney Lcn2 levels) than the 
reciprocal transplantation (n = 3 each). (F) In situ 
hybridization showing Lcn2 signal in medullary cells 
and ICs in LPS-challenged mice (paraffin in situ 
hybridization). Lcn2 RNA signal (dark purple stain) 
is denoted by arrowheads. (G) UPEC-GFP (green) 
bound TLR4+ (blue) cells in the CDs of C3H mice 1 
day after inoculation (original magnification, ×100). 
*P < 0.05; **P < 0.001. Scale bars: 10 μm.
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An antimicrobial role for A-ICs was also suggested by their 
prominent transcriptional and translational expression of Lcn2 
and the Lcn2-Luc2 reporter in different injuries, including infection 
(Figure 6, C–E), LPS treatment (Figure 9F), and aseptic damage to 
the kidney (15). The expression level of uLCN2 in fact depended 
on the IC, because Tcfcp2l1 deletion reduced uLCN2 (Figure 7C). 
In addition, both deletion of Tcfcp2l1 (Figure 7, A and B) and dele-
tion of Lcn2 (Figure 2A) resulted in excess uCFUs. Even after neu-
trophil ablation (15, 82), inoculation with UPEC still resulted in 
Lcn2 gene expression in the kidney and LCN2 protein in the urine 
(Figure 9E), demonstrating a contribution of kidney parenchyma 
to LCN2 expression. In summary, A-ICs can contribute to immune 
defense not only by urinary acidification (Figure 8), but also by 
prominently expressing LCN2 in different settings. Consequently, 
ICs are necessary for bacteriostasis.
The LCN2 protein is an unusual defense mechanism because 
of its specificity for a single virulence pathway. The bacteriostat-
ic activity of LCN2 depended on the expression of Ent, because 
unlike WT bacteria (Figure 2A), Ent-null bacteria grew equally well 
in Lcn2–/– and Lcn2+/+ littermates. These data suggested that con-
trol of UPEC growth depended on the relative expression levels of 
bacterial Ent and mammalian LCN2, because prominent LCN2 
expression would limit the contribution of Ent in favor of alterna-
tive bacterial Fe carriers (Figure 3A and ref. 69). In this light, the 
contribution of Ent to UPEC fitness in the setting of additional 
siderophores may have been underestimated, because the level of 
the Ent inhibitor LCN2 was unknown in previous studies (3, 43, 
81, 101, 102). The LCN2-Ent interaction is also likely to dominate 
LCN2 function, because the LCN2:Ent:Fe3+ complex was stable in 
acidified urine (Figure 2E), even at pH 4.5. Hence, coexpression of 
H+ and LCN2 by A-ICs might activate the LCN2-Ent interaction 
because other ligands, such as urinary catechols, would dissociate 
from LCN2 below pH 6.0 (103). In summary, LCN2 regulates bac-
terial growth in acidified urine by binding to Ent, although non-
Ent siderophore pathways must partially compensate. Moreover, 
LCN2 may have non–siderophore-dependent activities, such as 
chemotactic activities, which we have not evaluated, but remain 
compatible with our IC-LCN2 model (102).
It should also be noted that measurements of tissue homo-
genates and longitudinal measurements of the urine provided 
similar data in our assays, consistent with publications demon-
strating that uCFUs parallel bladder and kidney CFUs (67). How-
ever, LCN2 activity has only been tested in the soluble phase (40, 
45), rather than within tissues (104). The focus on extracellular 
LCN2 is due in part to the rapid accumulation of LCN2 protein 
(10 μM) in the media or in the urine or plasma after an inductive 
stimulus (e.g., LPS, ischemia, and UPEC inoculation; Figure 2B 
and refs. 40, 45), despite only weak intracellular staining. Conse-
quently, LCN2 most likely acts in the extracellular fluid. Hence, 
sampling the urine not only demonstrated the bacteriostatic pool 
of LCN2, but it also allowed us to simultaneously follow the time 
course of uCFU and uLCN2 expression in individual mice, which 
Figure 10
LCN2 induction. (A) CD (boxed region) 
and connecting segments contain 
A-ICs. (B) Systemic sepsis, cystitis, and 
pyelonephritis (UTI) activate A-ICs. Kid-
ney TLR4 expression is critical for the 
secretion of uLCN2 and cytokines 
and for the suppression of UTI. LCN2 
is secreted into the urine (apically) 
and is potentially also secreted into 
the circulation (basolaterally). Note 
that LCN2 and H+ secretion are both 
activated in UTI.
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provided internally controlled, longitudinal data. uCFU assays 
are also a well-known component of the definition of human UTI 
(e.g., >50,000 uCFUs in children; ref. 105).
While our present data demonstrated a role for A-ICs and kidney 
LCN2 in the control of urinary infections, the question of how 
kidney cells sense infection was still not resolved. To approach 
this problem, we capitalized on the natural differences between 
C57BL/6 mice, which are resistant to kidney colonization, and 
C3H mice, which are readily infected due to the Vurm1 locus (84). 
Hence, low-volume inocula (20 μl) resulted in few, if any, bacteria 
in the C57BL/6 kidney, while the same inocula resulted in infec-
tion of the C3H kidney (Figure 4, E and F). In both lines, however, 
LCN2 was consistently and abundantly expressed (Figure 4, A and 
C, and Figure 9C), as were a number of cytokines (Figure 4G and 
Figure 5C), despite obvious differences in bacterial colonization. 
Moreover, knockout of ICs in the C57BL/6 background (Figure 7, 
A and B) reduced uLCN2 expression (Figure 7C), confirming the 
contribution of the kidney, even in a model of cystitis. In short, 
regardless of the severity of the UTI, both C57BL/6 and C3H mice 
activated Lcn2 expression, suggestive of a shared sensing mecha-
nism in both lines.
The most important sensing mechanism is likely to be mediated 
by TLR4 expression. TLR4 was not only expressed by IC (Figure 9G 
and ref. 89), but was apparently required for LCN2 expression and 
for the suppression of infection. Lpsd defective mice had 5-fold less 
kidney Lcn2, but a 4-log-order increase in uCFUs, compared with 
Lpsn WT mice. These data are consistent with Flo et al., who found 
that Lcn2 is TLR4 dependent (45), and the groups of Hagberg (106) 
and Schilling (107), who demonstrated log-order increases in CFUs 
in Lpsd compared with Lpsn mice. In humans, Karoly et al. suggested 
that polymorphisms in human TLR4 increased the risk of UTI in 
children (108). In short, the most parsimonious explanation for 
LCN2 expression is the activation of TLR4 in CDs. In the case of 
C3H mice, prominent infection of the kidney induced the expres-
sion of Lcn2 and cytokines in a TLR4-dependent manner (Figure 9, 
B–D). In the case of C57BL/6 mice, we surmise that a qualitatively 
similar mechanism is active, despite the failure to demonstrate kid-
ney colonization. In other words, C57BL/6 Lcn2 expression could 
be activated by the circulation or the ascent of a small number of 
bacteria or LPS or fragments containing LPS. Non-TLR4 ligands 
may also play a role, because while the TLR4 mutation in the C3H 
mouse line (HeJ strain; refs. 83, 109, 110), markedly limited the 
expression of Lcn2, it did not abolish its expression. Exciting pre-
liminary observations indicated that Ent can stimulate cytokine 
expression in a cell line (111) and LCN2 expression in mice (Sup-
plemental Figure 4). This is an intriguing finding, because it would 
suggest that a specific defense (LCN2) is activated by its own cog-
nate bacterial ligand (Ent). Finally, it is also possible that sensing is 
caused by cytokine signaling to the kidney (e.g., Il8; refs. 112, 113). 
Notably, Il1 members were consistently induced in the bladder and 
kidneys of C3H and C57BL/6 mice (Figure 4G and Figure 5C). 
Regardless of mechanism, however, our data suggested that kid-
ney A-ICs play a part in the innate immune response to UTIs, even 
when few, if any, bacteria can be cultured from the kidney itself.
Earlier work of Safirstein, Heyman, Rosen, and others showed 
that the distal nephron can respond to a variety of injuries by 
expressing cytokines (114) and growth factors (115), activating 
ERK (116) and HIF (117), and redistributing corticomedullary 
circulation (118). Using mouse models, we showed that various 
injuries induce a cell-specific response in the CD, namely the 
activation of A-ICs (15). Here we show that stimulated A-ICs in 
turn limit bacterial growth by secreting LCN2 and H+ and other 
antimicrobials. Human diseases of A-ICs, such as chronic distal 
renal tubular acidosis, are characterized by recurrent UTI and 
pyelonephritis (119) as well as by kidney stones, making it difficult 
to determine whether the recurrent UTI is primarily due to a fail-
ure of A-IC function or secondarily due to the presence of kidney 
stones. Here, we showed that a defect in ICs can be a primary factor 
for the increased susceptibility of the urinary tract to infection.
It is well known that the gastrointestinal tract (Paneth cells), the 
frog skin, and the epididymis (clear cells) are populated by scat-
tered epithelia (120), which secrete acid-base, antimicrobial pep-
tides, or both types of bacteriostatic agents. In this context, we 
conclude that A-ICs represent another example of the innate cel-
lular defense, because they not only regulate acid-base homeosta-
sis (90), but also serve as a critical sentinels and effectors in UTIs, 
including both cystitis and pyelonephritis (Figure 10).
Methods
Mouse husbandry. Lcn2loxP/loxP, Lcn2–/–, C57BL/6, C3H/HeJ, C3H/HeOuJ, 
C3H/HeN, Tcfcp2l1loxP/loxP, Tcfcp2l1–/–, EIIa-flpe, Ksp-Cre, and Lcn2-Luc2/mC 
mice were generated and analyzed by protocols approved by the IACUC at 
Columbia University.
Generation of Lcn2loxP/loxP mice. We created a targeting vector to delete exons 
2–5 (a span of 2.1 kb) because this region contains important caliceal 
amino acids that bind Ent. Using a C57BL/6J library (RPCI-23; CHORI) 
and bacterial recombineering, a single loxP was inserted into intron 1, and 
frt-loxP-neo-frt-loxP was inserted into intron 5. The targeting construct was 
14.2 kb consisting of a (5′) 9.9-kb-long homology arm, a loxP in intron 1, 
exons 2–5, a 2-kb pGK-neo cassette flanked by frt-loxP-neo-frt-loxP, and final-
ly a (3′) 2.3-kb short homology arm. A third loxP site provided a backup in 
case flp was inefficient. The targeting vector was electroporated, and ES 
clones were selected with neo and validated by PCR. 13 heterozygous F1 
pups carrying targeted alleles (Lcn2+/loxP-flp) were generated from F0 mice 
and crossed with the flp deleter (Actb promoter–FLP B6; SJLTg [ACTFLPe] 
9205 Dym/J; JAX Mice stock no. 003800) that had been backcrossed to 
C57BL/6 for 5 generations to reduce genetic heterogeneity. The offspring 
Actb-flp;Lcn2loxP/+ mice were mated with C57BL/6 mice to eliminate Actb-
flp, and then brother-sister mating produced Lcn2loxP/loxP mice. Lcn2 was 
deleted by breeding Lcn2loxP/loxP to EIIa-Cre mice (B6.FVB-Tg[EIIa-cre] 
C5379Lmgd/J; JAX Mice stock no. 003724).
Generation of Tcfcp2l1loxP/loxP mice. We generated a knockout of Tcfp2l1 by 
inserting loxP sites flanking exons 3, 4, and 5 (∼1.8 kb) using BAC recom-
bineering (BAC clone no. RP24-291G6; CHORI). This strategy was chosen 
in order to delete the CP2 conserved functional domain and to create an 
open reading frame shift. For cloning and ES cell generation, in brief, the 
endogenous loxP site in the BAC DNA was removed using a spectinomy-
cin cassette from Columbia University Transgenic Facility, and loxP sites 
were subsequently introduced using loxP-neo-loxP (LNL) and frt-neo-frt-
loxP (FNFL) cassettes. The vector was introduced into mouse KV1 ES cells 
(generated by Columbia University Transgenic Facility); neo cassettes were 
eventually removed in ES cells with Cre recombinase and in the mouse by 
mating with the EIIa-flpe deleter. Tcfp2l1 was deleted using Ksp-Cre (Jack-
son Labs), and the deletion was confirmed by PCR and immunostaining 
for Tcfcp2l1 (AF5726; R&D Systems). The absence of ICs was detected by 
immunostaining for H+ATPase (ATP6v1b1; Santa Cruz). TROMA1 (Krt8; 
Developmental Studies Hybridoma Bank) was used as a pan-CD marker.
Imaging of live Lcn2-Luc2 reporter mice. Lcn2-Luc2 reporter mice (15) were 
injected i.p. with 150 mg/kg D-luciferin (Caliper Life Sciences) in PBS (pH 
7.0), anesthetized (2.5% isofluorane), and then imaged for 30 s using the 
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cillin-streptomycin, and 46 mg/l L-valine for 24 hours. Cells were treated 
for 24 hours with either living or heat-killed (30 minutes boiling) CFT073 
UPEC (5 × 106 CFUs) or with LPS (4 μg/ml) and NF-κB inhibitor, analog 
31 (5 μM) (15). Luciferase substrate (Luciferase Assay System; Promega) 
was added, and luminescence from Luc2 was imaged in a IVIS Spectrum 
optical imaging system (PerkinElmer).
In vitro ICs. Rabbit ICs Clone C were obtained from S. Vijayakumar (Uni-
versity of Rochester, Rochester, New York, USA), maintained at 32°C, and 
then seeded on Corning Transwell no. 3412 at a density of 5 × 105 cells/
cm2 (high density) in DMEM/F12 50:50 (MT10090CV; Mediatech Cellgro) 
with 10% heat-inactivated FBS (Invitrogen), 1% penicillin-streptomycin, 
20 mg/l hydrocortisone, and an insulin, transferrin, and selenium sup-
plement (Lonza) at 40°C (to inactivate the T antigen). Cells were serum 
starved prior to treatment, and RNA was extracted using an Ambion kit 
(AM1560) with DNAse digestion.
Fe quantification. Pooled C3H/HeN urine (n = 15) was collected by clean 
catch and centrifuged for 10 minutes at 10,000 g. Urine, protein, and media 
Fe concentrations were measured by a Graphite Furnace Atomic Absorp-
tion Spectrophotometer (GFAAS), model Analyst 800 (PerkinElmer) by the 
Trace Metals Core Facility at the Columbia University Mailman School of 
Public Health.
Western blot. Human urines were analyzed using nonreducing 4%–15% 
tris-HCL gels (Bio-Rad Laboratories) and monoclonal human LCN2 
(1:1,000; BPD-HYB-211-01-02; Enzo Lifesciences). LCN2 was reproducibly 
detected to 0.4 ng/lane. Mouse urine LCN2 was detected by the polyclonal 
antibody (1:1,000; AF1857; R&D Systems), which has lower sensitivity than 
the anti-human antibodies. LCN2 protein was semiquantified by compari-
son with mouse or human LCN2 protein standards using Image J (NIH).
In situ hybridization and immunohistochemistry. Lcn2 RNA was detected 
using digoxigenin-labeled antisense riboprobes (Roche Applied Biosys-
tems) from cDNAs encoding LCN2 (exon 1–7, 566 bp) by linearization with 
XhoI followed by T7 RNA polymerase as previously described.
Frozen and paraffin-embedded sections were used for in situ hybridiza-
tion. Frozen sections were used for immunohistochemical analyses with 
vATPase B1/2 (1:50; Santa Cruz Biotechnology) and TLR4 (1:50; Abcam) 
antibodies. DAPI and TOTO3 (1:1,000) were used for nuclear staining.
Real-time PCR analysis. Total RNA was isolated with mirVANA (for eukary-
otic cells) or ribopure (for bacteria) RNA extraction kits (Ambion). First-
strand cDNA was synthesized with Superscript III (Invitrogen). Real-time 
PCR was performed in a 7500 Fast (Applied Biosystems) with SYBR green 
supermix reagent (Fisher) or Gene Expression Master Mix (Invitrogen) and 
primers (Supplemental Table 1) using Actb (eukaryotic cells) or gapA (bac-
teria) as internal controls. Fold amplification of transcripts was measured 
by the ΔΔCt method.
Ent induction of Lcn2. Ent (30 μg) in 0.5 ml saline buffer (Sigma-Aldrich) 
was introduced in mice i.p. Kidneys were harvested 4–6, 8, or 12 hours after 
treatment. Total RNA was isolated from kidneys using TRIzol reagent 
(Invitrogen) according to the manufacturer’s instruction. First-strand 
cDNA was synthesized using the High Capacity Reverse Transcription Kit 
(Applied Biosystems). Real-time PCR was performed in a LightCycler 96 
(Roche) with Taqman gene expression master mix reagent (Applied Bio-
systems) and primers using Actb (eukaryotic cells) as internal control. Fold 
amplification of transcripts was measured by the ΔΔCt method.
Statistics. We evaluated our entire cohort of Emergency Department patients, 
as well as a subset with normal lab indices (serum creatinine and proteinuria), 
over a 7-day hospital course. UTI was defined by LE 1+ or 2+ and urinary Cx 
containing known urinary pathogens. Analyses used SPSS version 16.0. Con-
tinuous data were log-transformed prior to analysis, but presented as non–
log-transformed values. 2-tailed t test for unequal variances was used for com-
parisons (Welsh’s t test). A P value less than 0.05 was considered significant. 
PhotonIMAGER optical imaging system (Biospace Labs) with open filter 
position for luminescence. Regions of interest (ROIs) were quantified 
using bundled photo acquisition software (BioSpace Labs). A CCD camera 
digitizer measured the ROIs, and counts were converted to physical units 
of radiance in photons/s/cm2/steradian.
Kidney cross-transplantation. To evaluate kidney TLR4 expression, we cross-
transplanted Lpsd kidneys into Lpsn controls and vice versa. The surgical 
cross-transplants (15) were monitored for 2 weeks until serum creatinine 
stabilized at 0.2 mg/dl and uLCN2 was undetectable prior to challenge 
with LPS (1 mg/kg i.p.).
UTIs. We used 8- to 16-week-old female C57BL/6, Lcn2–/–, Lcn2-Luc2 
reporter, C3H/HeJ, C3H/HeN, and C3H/HeOuJ mice. Bacteria (20 μl; con-
taining 1 × 107 CFUs or heat killed) were introduced into the bladders of 
anesthetized mice through a soft polyethylene catheter (0.61 mm outer 
diameter; Intramedic). CFUs in kidney homogenates or in urine (collected 
directly from mice) were quantified by serial dilution on LB agar plates. 
Mutant entF-CFT073 UPEC was obtained from S. Payne (University of 
Texas at Austin, Austin, Texas, USA; ref. 66). The mutant was constructed 
by insertion of the Kan cassette and confirmed by PCR (entF-1792 forward, 
5′-GCTTATATCATCTTCACCTCAGGTTCCACC-3′; entF-3115 reverse, 
5′-GCTGTCTTCTTCACCATCAATAATCGTTGC-3′) (66).
Inhibition of bacterial growth in vitro. A single colony of CFT073 UPEC was 
grown in M9 or in urine to log phase. Bacteria were pelleted and resuspend-
ed in either M9 or urine and monitored in a 96-well plate (Tecan Infinite 
200 Pro). Notably, CFT073 UPEC grown to log phase in LB carry over Fe 
into downstream assays.
Generation of a luxCDABE-labeled CFT073 UPEC strain. The mini-Tn5-
luxCDABE transposon was delivered to CFT073 UPEC (ATCC 700928) 
by conjugation with the donor strain E. coli S17-1 λ-pir (pUTmini-Tn5-
luxCDABE-km2). The donor and CFT073 UPEC recipient cells were grown 
overnight in 5 ml LB broth at 37°C prior to biparental mating. Harvested 
cells were gently washed twice in LB and resuspended in one-tenth the 
original culture volume. A mixture of donor and recipient cells (1:5) was 
gently mixed, spot-inoculated onto the surface of nitrocellulose filters 
(0.13 mm; catalog no. VMWP01300; Millipore), and incubated at 37°C for 
6–8 hours. To select for CFT073 UPEC transconjugants, cells were scraped 
off the filters, washed twice in LB, and plated onto LB agar plates contain-
ing 50 μg/ml kanamycin (Km2) for 24–48 hours. Highly bioluminescent 
transconjugants were identified in an IVIS Spectrum (PerkinElmer) and 
further purified by subculturing twice on LB containing 50 μg/ml kanamy-
cin. The CFT073 UPEC-lux strains were further differentiated from donor 
strains by negative growth on LB agar with 100 μg/ml ampicillin.
LCN2 protein production. Recombinant protein was produced in BL21 
E. coli transformed with mouse or human LCN2 cDNA lacking 29–amino 
acid signal sequence (pGEX-4T-3-vector) and grown for 16 hours at 37°C 
in Modified Terrific Broth supplemented with 150 μM Fe to inhibit the 
endogenous production of Ent. IPTG (0.2 mM final concentration) was 
added for 5 hours. Bacterial pellets were lysed by sonication in lysis buffer, 
followed by Triton-X 100 (0.5%) treatment for 30 minutes on ice. Super-
natants were collected after high-speed centrifugation and filter sterilized 
(0.45 μm). LCN2-GST was purified by binding to glutathione sepharose 
beads, followed by cleavage of the GST tag with thrombin. Released pro-
tein was fractionated by a Sephacryl S100HR column. Ent (EMC Micro-
collections gmbh) capture by LCN2 was tested at a 1:1:1 Ent:Fe:LCN2 
ratio. The complex was washed 5 times on a 10-k micron, and binding was 
detected by its red coloration or by retention of 55Fe.
Isolation and culture of cells. Lcn2-Luc2 reporter mice (8–12 weeks of age) 
were perfused with PBS, and kidney cells were isolated with collagenase 
(2 mg/ml; Sigma-Aldrich) and cultured (1 × 105 cells/well in 24-well plates; 
Falcon) in DMEM/F12 medium supplemented with 10% FBS, 1% peni-
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